Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) acquired Medicis Pharmaceutical Corporation ("Medicis") following the approval of the transaction by stockholders of Medicis at the special meeting held on December 7, 2012. Valeant acquired all of the common stock of Medicis outstanding at the time of the completion of the acquisition for $44.00 per share in cash. For more information, please click here.

All trademarks are the property of their respective owners.